TransCon IL-2 β/γ
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for TransCon IL-2 β/γ, covering 2025-08-01 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies [Phase 1, Phase 2]